


*SEPTEMBER 2017*

RESEARCH  
REPORT

---



Medical Laboratory, Cardiac, Molecular  
Diagnostic and Genomic Testing Services.  
Strategies & Trends. Price & Volume Forecasts  
by Laboratory Department by Country.  
2017 to 2022 - Global Version



Table of Contents

1. Introduction and Market Definition ..... 15

    1.1 The Growing Demand for Clinical Testing ..... 16

    1.2 Defining the Opportunity ..... 18

        1.2.1 Volumes ..... 18

        1.2.2 Prices ..... 18

        1.2.3 Revenue Market Size ..... 19

    1.3 Methods and Sources ..... 19

        1.3.1 Authors ..... 19

        1.3.2 Sources ..... 20

    1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective ..... 21

        1.3.1 U.S. Medicare Expenditures for Clinical Testing ..... 21

2. Overview of a Dynamic Market ..... 23

    2.1 Market Players – Roles & Impacts ..... 24

        2.1.1 Supplier/pharmaceutical ..... 24

        2.1.2 Independent lab specialized/esoteric ..... 25

        2.1.3 Independent lab national/regional ..... 25

        2.1.4 Independent lab analytical ..... 25

        2.1.5 Public National/regional lab ..... 26

        2.1.6 Hospital lab ..... 26

        2.1.7 Physician lab ..... 26

        2.1.8 Audit body ..... 26

    2.2 Segmentation – Different Approaches ..... 28

        2.2.1 Traditional Market Segmentation ..... 28

        2.2.2 Laboratory Focus and Segmentation ..... 28

    2.3 Structure of Clinical Testing Industry ..... 30

        2.3.1 The Hospital Lab – Share of the Pie ..... 30

        2.3.2 Key Role for Economies of Scale ..... 30

        2.3.3 Physician Office Lab’s are Still Here ..... 32

        2.3.4 Physician’s and POCT – Reviving Patient Service in China ..... 32

    2.4 Profiles of Key Companies ..... 33

        2.4.1 Quest Diagnostics ..... 33

        2.4.2 Laboratory Corporation of America ..... 36

        2.4.3 Lifelabs Medical Laboratory Services ..... 39

        2.4.4 ACM Medical Laboratory ..... 41

        2.4.5 Spectra Laboratories, Inc. .... 43

        2.4.6 Bio-Reference Laboratories, Inc. .... 45

        2.4.7 CompuNet Clinical Laboratories, LLC ..... 48

        2.4.8 Genzyme Corporation ..... 50

        2.4.9 Sonic Healthcare Limited ..... 53

        2.4.10 Exagen Diagnostics, Inc. .... 55

        2.4.11 Clongen Laboratories LLC ..... 57

        2.4.12 Clinical Reference Laboratory, Inc. .... 58

2.4.13 Mid America Clinical Laboratories, LLC ..... 61

2.4.14 Miraca Life Sciences, Inc. .... 63

2.4.15 Psychemedics Corp. .... 66

2.4.16 Aurora Diagnostics, LLC ..... 68

2.4.17 DL Reference Laboratory..... 70

2.4.18 Myriad Genetics, Inc. .... 71

2.4.19 Bioscientia Institut fuer Medizinische Diagnostik GmbH ..... 73

2.4.20 Acibadem Labmed Laboratory..... 75

2.4.21 Eurofins Scientific..... 77

2.4.22 The Doctor’s Laboratory (Sonic Healthcare U.K.) ..... 80

2.4.23 Pathology Inc..... 81

2.4.24 Gribbles Pathology ..... 83

2.4.25 B.P. CLINICAL LAB ..... 84

2.4.26 Diagnósticos da América (DASA) ..... 85

2.4.27 American Bio-Clinical Laboratories, Int'l ..... 87

2.4.28 Adicon Clinical Laboratories ..... 88

2.4.29 Dian Diagnostics ..... 89

2.4.30 Kingmed Diagnostics ..... 91

2.4.31 Ascend Clinical, LLC..... 93

2.4.32 Unilabs SA ..... 95

2.4.33 American Pathology Partners, Inc..... 97

2.4.34 Integrated Regional Laboratories, Inc. .... 99

2.4.35 Viracor Laboratories..... 101

2.4.36 Neogenomics ..... 102

2.4.37 Genomic Health, Inc..... 104

2.4.38 ARUP Laboratories, Inc. .... 106

2.4.39 Enzo Biochem, Inc. .... 109

2.5 National and Regional Diversity ..... 111

3. Trends Driving a Changing Market ..... 113

3.1 Growth Is Pushed From Many Sides ..... 114

3.1.1 Understanding the Impact of Aging Population..... 114

3.1.2 Economic growth a Key Driver..... 115

3.1.3 Point of Care Testing can increase demand ..... 115

3.1.4 Alternative Medicine Creates Testing Opportunity ..... 115

3.1.5 Esoteric Testing Moving Mainstream ..... 116

3.1.6 Genetic Based Testing Creates New Department and New Discipline..... 116

3.2 Factors At Work To Shrink The Market..... 117

3.2.1 Lower costs trend to continue ..... 117

3.2.2 Economic or population contraction. .... 117

3.2.3 Testing usage analysis curtailing growth. .... 118

3.2.4 Wellness has a downside..... 118

3.2.5 Test Displacement Impacts Important..... 118

3.2.6 Point of Care Testing..... 118

3.3 Automation ..... 119

- 3.3.1 Stranded LIMS Investment ..... 119
- 3.3.2 Software as a Service ..... 119
- 3.3.3 Physician Office and Access Systems..... 119
- 3.4 Environment and Evolution..... 121
- 3.5 Diagnostic Technology Development ..... 122
  - 3.5.1 Next Generation Sequencing Fuels a Revolution..... 123
  - 3.5.2 Impact of NGS on pricing ..... 124
  - 3.5.3 POCT/Self Testing Disruptive Force ..... 124
  - 3.5.4 Pharmacogenomics Blurs Diagnosis and Treatment..... 125
  - 3.5.5 CGES Testing, A Brave New World..... 125
  - 3.5.6 Molecular Diagnostics Technologies At The Forefront of Growth ..... 126
  - 3.5.7 Biochips/Giant magneto resistance based assay ..... 127
- 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments..... 128
  - 4.1 Recent Developments – Importance and How to Use This Section..... 129
    - 4.1.1 Importance of These Developments..... 129
    - 4.1.2 How to Use This Section..... 129
  - 4.2 LabCorp explores acquisition of clinical trials firm PPD..... 129
  - 4.3 Digipath Enters into Letter of Intent to Acquire Clinical Lab Companies..... 130
  - 4.4 PSP to acquire European medical lab services company ..... 131
  - 4.5 Mars, Incorporated to Acquire VCA Inc. .... 132
  - 4.6 Caprion Biosciences Acquires the Immune Monitoring Laboratory from ImmuneHealth..... 134
  - 4.7 Takara Bio USA Holdings and Rubicon Genomics Announce Merger Agreement ..... 136
  - 4.8 Instrumentation Laboratory Acquires CA Casyso AG..... 137
  - 4.9 Schryver Medical Completes Acquisitions of Professional Clinical Laboratory, Inc..... 139
  - 4.10 Grail, Illumina’s billion-dollar diagnostics startup..... 140
  - 4.11 Grifols acquires Hologic’s blood screening unit for \$1.85bn..... 142
  - 4.12 Bio-Rad Laboratories to buy US firm RainDance Technologies ..... 142
  - 4.13 Abbott Laboratories to buy St. Jude Medical for \$25 billion ..... 143
  - 4.14 CombiMatrix Gets Serious About Potential M&A Options in Wake of \$8M Offering..... 144
  - 4.15 Abbott to Acquire Alere, Becoming Leader in Point of Care Testing ..... 146
  - 4.16 Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger..... 147
  - 4.17 LabCorp Agrees to Acquire Assets of Pathology Inc..... 150
  - 4.18 NeoGenomics Completes Acquisition of Clariant, Inc. .... 151
  - 4.19 FDA Gets Pushback on Move to Regulate Lab Developed Tests ..... 151
  - 4.20 Cancer Genetics, Inc. Announces Partnership..... 153
  - 4.21 Theranos plans to close all its clinical labs..... 154
  - 4.22 Forte Capital Lowers stake in Laboratory Corp. .... 156
  - 4.23 US Oncology Network Selects Myriad Genetics ..... 157
  - 4.24 Pyxant Labs Commences Clinical Laboratory Testing Services..... 158
  - 4.25 Viewics Launches Diabetes Management ..... 159
  - 4.26 Alpha Genomix And Rx30 Partner..... 160
  - 4.27 LabCorp Doubles Testing Capacity Of Covance ..... 161
  - 4.28 LabCorp to acquire clinical laboratories from Mount Sinai..... 162
  - 4.29 PerkinElmer to buy Germany's Euroimmun for about \$1.3 billion..... 163

4.30 LabCorp to Acquire Chiltern for Approximately \$1.2 Billion in Cash..... 164

4.31 Precipio Diagnostics and Transgenomic Complete Merger ..... 165

4.32 \$550 Dock Turns a Smartphone into a Medical Lab ..... 167

4.33 LabCorp & Interpace Extend Deal, Boost Cancer Portfolio ..... 167

5. Country Market Sizes – North America 2014 to 2022 ..... 169

5.1 United States of America 2014 to 2022..... 170

5.1.1 Clinical Chemistry – Volumes, Prices, Revenues ..... 170

5.1.2 Microbiology – Volumes, Prices, Revenues ..... 170

5.1.3 Hematology – Volumes, Prices, Revenues ..... 170

5.1.4 Anatomic Pathology – Volumes, Prices, Revenues ..... 171

5.1.5 Molecular Diagnostics – Volumes, Prices, Revenues ..... 171

5.1.6 All Clinical Testing – Volumes, Prices, Revenues ..... 171

5.1.7 Cardiac Biomarkers – Volumes, Prices, Revenues ..... 172

5.1.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues..... 172

5.1.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues ..... 172

5.2 Canada 2014 to 2022 ..... 173

5.2.1 Clinical Chemistry – Volumes, Prices, Revenues ..... 173

5.2.2 Microbiology – Volumes, Prices, Revenues ..... 173

5.2.3 Hematology – Volumes, Prices, Revenues ..... 173

5.2.4 Anatomic Pathology – Volumes, Prices, Revenues ..... 174

5.2.5 Molecular Diagnostics – Volumes, Prices, Revenues ..... 174

5.2.6 All Clinical Testing – Volumes, Prices, Revenues ..... 174

5.2.7 Cardiac Biomarkers – Volumes, Prices, Revenues ..... 175

5.2.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues..... 175

5.2.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues ..... 175

6. Country Markets – Europe 2014 to 2022..... 176

6.1 France 2014 to 2022 ..... 177

6.1.1 Clinical Chemistry – Volumes, Prices, Revenues ..... 177

6.1.2 Microbiology – Volumes, Prices, Revenues ..... 177

6.1.3 Hematology – Volumes, Prices, Revenues ..... 177

6.1.4 Anatomic Pathology – Volumes, Prices, Revenues ..... 178

6.1.5 Molecular Diagnostics – Volumes, Prices, Revenues ..... 178

6.1.6 All Clinical Testing – Volumes, Prices, Revenues ..... 178

6.1.7 Cardiac Biomarkers – Volumes, Prices, Revenues ..... 179

6.1.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues..... 179

6.1.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues ..... 179

6.2 Germany 2014 to 2022 ..... 180

6.2.1 Clinical Chemistry – Volumes, Prices, Revenues ..... 180

6.2.2 Microbiology – Volumes, Prices, Revenues ..... 180

6.2.3 Hematology – Volumes, Prices, Revenues ..... 180

6.2.4 Anatomic Pathology – Volumes, Prices, Revenues ..... 181

6.2.5 Molecular Diagnostics – Volumes, Prices, Revenues ..... 181

6.2.6 All Clinical Testing – Volumes, Prices, Revenues ..... 181

6.2.7 Cardiac Biomarkers – Volumes, Prices, Revenues ..... 182

6.2.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	182
6.2.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	182
6.3 United Kingdom 2014 to 2022 .....	183
6.3.1 Clinical Chemistry – Volumes, Prices, Revenues.....	183
6.3.2 Microbiology – Volumes, Prices, Revenues .....	183
6.3.3 Hematology – Volumes, Prices, Revenues .....	183
6.3.4 Anatomic Pathology – Volumes, Prices, Revenues .....	184
6.3.5 Molecular Diagnostics – Volumes, Prices, Revenues.....	184
6.3.6 All Clinical Testing – Volumes, Prices, Revenues .....	184
6.3.7 Cardiac Biomarkers – Volumes, Prices, Revenues.....	185
6.3.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	185
6.3.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	185
6.4 Spain 2014 to 2022 .....	186
6.4.1 Clinical Chemistry – Volumes, Prices, Revenues.....	186
6.4.2 Microbiology – Volumes, Prices, Revenues .....	186
6.4.3 Hematology – Volumes, Prices, Revenues .....	186
6.4.4 Anatomic Pathology – Volumes, Prices, Revenues .....	187
6.4.5 Molecular Diagnostics – Volumes, Prices, Revenues.....	187
6.4.6 All Clinical Testing – Volumes, Prices, Revenues .....	187
6.4.7 Cardiac Biomarkers – Volumes, Prices, Revenues.....	188
6.4.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	188
6.4.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	188
6.5 Italy 2014 to 2022 .....	189
6.5.1 Clinical Chemistry – Volumes, Prices, Revenues.....	189
6.5.2 Microbiology – Volumes, Prices, Revenues .....	189
6.5.3 Hematology – Volumes, Prices, Revenues .....	189
6.5.4 Anatomic Pathology – Volumes, Prices, Revenues .....	190
6.5.5 Molecular Diagnostics – Volumes, Prices, Revenues.....	190
6.5.6 All Clinical Testing – Volumes, Prices, Revenues .....	190
6.5.7 Cardiac Biomarkers – Volumes, Prices, Revenues.....	191
6.5.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	191
6.5.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	191
6.6 Russia 2014 to 2022.....	192
6.6.1 Clinical Chemistry – Volumes, Prices, Revenues.....	192
6.6.2 Microbiology – Volumes, Prices, Revenues .....	192
6.6.3 Hematology – Volumes, Prices, Revenues .....	192
6.6.4 Anatomic Pathology – Volumes, Prices, Revenues .....	193
6.6.5 Molecular Diagnostics – Volumes, Prices, Revenues.....	193
6.6.6 All Clinical Testing – Volumes, Prices, Revenues .....	193
6.6.7 Cardiac Biomarkers – Volumes, Prices, Revenues.....	194
6.6.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	194
6.6.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	194
6.7 Remainder of Europe and Former Soviet Union 2014 to 2022.....	195
6.7.1 Clinical Chemistry – Volumes, Prices, Revenues.....	195

6.7.2 Microbiology – Volumes, Prices, Revenues .....	195
6.7.3 Hematology – Volumes, Prices, Revenues .....	195
6.7.4 Anatomic Pathology – Volumes, Prices, Revenues .....	196
6.7.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	196
6.7.6 All Clinical Testing – Volumes, Prices, Revenues .....	196
6.7.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	197
6.7.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	197
6.7.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	197
7. Country Markets – Asia Pacific 2014 to 2022 .....	198
7.1 China 2014 to 2022 .....	199
7.1.1 Clinical Chemistry – Volumes, Prices, Revenues .....	199
7.1.2 Microbiology – Volumes, Prices, Revenues .....	199
7.1.3 Hematology – Volumes, Prices, Revenues .....	199
7.1.4 Anatomic Pathology – Volumes, Prices, Revenues .....	200
7.1.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	200
7.1.6 All Clinical Testing – Volumes, Prices, Revenues .....	200
7.1.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	201
7.1.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	201
7.1.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	201
7.2 Japan 2014 to 2022 .....	202
7.2.1 Clinical Chemistry – Volumes, Prices, Revenues .....	202
7.2.2 Microbiology – Volumes, Prices, Revenues .....	202
7.2.3 Hematology – Volumes, Prices, Revenues .....	202
7.2.4 Anatomic Pathology – Volumes, Prices, Revenues .....	203
7.2.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	203
7.2.6 All Clinical Testing – Volumes, Prices, Revenues .....	203
7.2.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	204
7.2.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	204
7.2.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	204
7.3 South Korea 2014 to 2022 .....	205
7.3.1 Clinical Chemistry – Volumes, Prices, Revenues .....	205
7.3.2 Microbiology – Volumes, Prices, Revenues .....	205
7.3.3 Hematology – Volumes, Prices, Revenues .....	205
7.3.4 Anatomic Pathology – Volumes, Prices, Revenues .....	206
7.3.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	206
7.3.6 All Clinical Testing – Volumes, Prices, Revenues .....	206
7.3.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	207
7.3.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	207
7.3.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	207
7.4 India 2014 to 2022 .....	208
7.4.1 Clinical Chemistry – Volumes, Prices, Revenues .....	208
7.4.2 Microbiology – Volumes, Prices, Revenues .....	208
7.4.3 Hematology – Volumes, Prices, Revenues .....	208
7.4.4 Anatomic Pathology – Volumes, Prices, Revenues .....	209

7.4.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	209
7.14.6 All Clinical Testing – Volumes, Prices, Revenues .....	209
7.4.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	210
7.4.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	210
7.4.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	210
7.5 Australia 2014 to 2022.....	211
7.5.1 Clinical Chemistry – Volumes, Prices, Revenues .....	211
7.5.2 Microbiology – Volumes, Prices, Revenues .....	211
7.5.3 Hematology – Volumes, Prices, Revenues .....	211
7.5.4 Anatomic Pathology – Volumes, Prices, Revenues .....	212
7.5.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	212
7.5.6 All Clinical Testing – Volumes, Prices, Revenues .....	212
7.5.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	213
7.5.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	213
7.5.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	213
7.6 Rest of Asia Pacific 2014 to 2022 .....	214
7.6.1 Clinical Chemistry – Volumes, Prices, Revenues .....	214
7.6.2 Microbiology – Volumes, Prices, Revenues .....	214
7.6.3 Hematology – Volumes, Prices, Revenues .....	214
7.6.4 Anatomic Pathology – Volumes, Prices, Revenues .....	215
7.6.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	215
7.6.6 All Clinical Testing – Volumes, Prices, Revenues .....	215
7.6.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	216
7.6.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	216
7.6.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	216
8. Country Markets – Latin America, Africa & The Middle East 2014 to 2022 .....	217
8.1 Brazil 2014 to 2022 .....	218
8.1.1 Clinical Chemistry – Volumes, Prices, Revenues .....	218
8.1.2 Microbiology – Volumes, Prices, Revenues .....	218
8.1.3 Hematology – Volumes, Prices, Revenues .....	218
8.1.4 Anatomic Pathology – Volumes, Prices, Revenues .....	219
8.1.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	219
8.1.6 All Clinical Testing – Volumes, Prices, Revenues .....	219
8.1.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	220
8.1.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues.....	220
8.1.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	220
8.2 Mexico 2014 to 2022 .....	221
8.2.1 Clinical Chemistry – Volumes, Prices, Revenues .....	221
8.2.2 Microbiology – Volumes, Prices, Revenues .....	221
8.2.3 Hematology – Volumes, Prices, Revenues .....	221
8.2.4 Anatomic Pathology – Volumes, Prices, Revenues .....	222
8.2.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	222
8.2.6 All Clinical Testing – Volumes, Prices, Revenues .....	222
8.2.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	223



8.2.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	223
8.2.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	223
8.3 Remainder of Latin America 2014 to 2022 .....	224
8.3.1 Clinical Chemistry – Volumes, Prices, Revenues .....	224
8.3.2 Microbiology – Volumes, Prices, Revenues .....	224
8.3.3 Hematology – Volumes, Prices, Revenues .....	224
8.3.4 Anatomic Pathology – Volumes, Prices, Revenues .....	225
8.3.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	225
8.3.6 All Clinical Testing – Volumes, Prices, Revenues .....	225
8.3.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	226
8.3.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	226
8.3.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	226
8.4 Africa & The Middle East 2014 to 2022 .....	227
8.4.1 Clinical Chemistry – Volumes, Prices, Revenues .....	227
8.4.2 Microbiology – Volumes, Prices, Revenues .....	227
8.4.3 Hematology – Volumes, Prices, Revenues .....	227
8.4.4 Anatomic Pathology – Volumes, Prices, Revenues .....	228
8.4.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	228
8.4.6 All Clinical Testing – Volumes, Prices, Revenues .....	228
8.4.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	229
8.4.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	229
8.4.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	229
9. Global Market Summary 2014 to 2022 .....	230
9.1 Global Market 2014 to 2022 .....	231
9.1.1 Clinical Chemistry – Volumes, Prices, Revenues .....	231
9.1.2 Microbiology – Volumes, Prices, Revenues .....	231
9.1.3 Hematology – Volumes, Prices, Revenues .....	231
9.1.4 Anatomic Pathology – Volumes, Prices, Revenues .....	232
9.1.5 Molecular Diagnostics – Volumes, Prices, Revenues .....	232
9.1.6 All Clinical Testing – Volumes, Prices, Revenues .....	232
9.1.7 Cardiac Biomarkers – Volumes, Prices, Revenues .....	233
9.1.8 Molecular Diagnostic Oncology – Volumes, Prices, Revenues .....	233
9.1.9 Molecular Diagnostic Genetics – Volumes, Prices, Revenues .....	233
10. The Future of the Clinical Laboratory .....	234
Appendices .....	235
I. United States Medicare System: January 2017 Clinical Laboratory Fees Schedule – National Limit and Midpoint .....	235

Table of Tables

Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 (\$Billion) .....	22
Table 2 Market Players by Type .....	24

Table 3 Clinical Laboratory Departments and Segments ..... 28

Table 4 Laboratory Management Focus – Different Approaches..... 29

Table 5 Key Segmentation Variables Going Forward ..... 29

Table 6 Factors Affecting Local Clinical Testing Demand ..... 111

Table 7 Seven Factors Driving Growth ..... 114

Table 8 Alternative Medicine Creates New Clinical Testing Markets ..... 116

Table 9 Six Factors Limiting Growth ..... 117

Table 10 Key Diagnostic Laboratory Technology Trends..... 122

Table 11 Next Generation Sequencing Technologies – Speed and Cost..... 123

Table 12 Key Point of Care Testing Uses..... 124

Table 13 Clinical Application Areas for Molecular Diagnostics..... 126

Table 14 Clinical Chemistry - Volume Price and Revenue Forecast ..... 170

Table 15 Microbiology - Volume Price and Revenue Forecast..... 170

Table 16 Hematology - Volume Price and Revenue Forecast ..... 170

Table 17 Anatomic Pathology - Volume Price and Revenue Forecast..... 171

Table 18 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 171

Table 19 All Clinical Testing - Volume Price and Revenue Forecast ..... 171

Table 20 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 172

Table 21 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 172

Table 22 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 172

Table 23 Clinical Chemistry - Volume Price and Revenue Forecast ..... 173

Table 24 Microbiology - Volume Price and Revenue Forecast..... 173

Table 25 Hematology - Volume Price and Revenue Forecast ..... 173

Table 26 Anatomic Pathology - Volume Price and Revenue Forecast..... 174

Table 27 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 174

Table 28 All Clinical Testing - Volume Price and Revenue Forecast ..... 174

Table 29 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 175

Table 30 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 175

Table 31 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 175

Table 32 Clinical Chemistry - Volume Price and Revenue Forecast ..... 177

Table 33 Microbiology - Volume Price and Revenue Forecast..... 177

Table 34 Hematology - Volume Price and Revenue Forecast ..... 177

Table 35 Anatomic Pathology - Volume Price and Revenue Forecast..... 178

Table 36 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 178

Table 37 All Clinical Testing - Volume Price and Revenue Forecast ..... 178

Table 38 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 179

Table 39 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 179

Table 40 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 179

Table 41 Clinical Chemistry - Volume Price and Revenue Forecast ..... 180

Table 42 Microbiology - Volume Price and Revenue Forecast..... 180

Table 43 Hematology - Volume Price and Revenue Forecast ..... 180

Table 44 Anatomic Pathology - Volume Price and Revenue Forecast..... 181

Table 45 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 181

Table 46 All Clinical Testing - Volume Price and Revenue Forecast ..... 181

Table 47 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 182

Table 48 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 182

Table 49 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 182

Table 50 Clinical Chemistry - Volume Price and Revenue Forecast ..... 183

Table 51 Microbiology - Volume Price and Revenue Forecast..... 183

Table 52 Hematology - Volume Price and Revenue Forecast ..... 183

Table 53 Anatomic Pathology - Volume Price and Revenue Forecast..... 184

Table 54 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 184

Table 55 All Clinical Testing - Volume Price and Revenue Forecast ..... 184

Table 56 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 185

Table 57 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 185

Table 58 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 185

Table 59 Clinical Chemistry - Volume Price and Revenue Forecast ..... 186

Table 60 Microbiology - Volume Price and Revenue Forecast..... 186

Table 61 Hematology - Volume Price and Revenue Forecast ..... 186

Table 62 Anatomic Pathology - Volume Price and Revenue Forecast..... 187

Table 63 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 187

Table 64 All Clinical Testing - Volume Price and Revenue Forecast ..... 187

Table 65 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 188

Table 66 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 188

Table 67 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 188

Table 68 Clinical Chemistry - Volume Price and Revenue Forecast ..... 189

Table 69 Microbiology - Volume Price and Revenue Forecast..... 189

Table 70 Hematology - Volume Price and Revenue Forecast ..... 189

Table 71 Anatomic Pathology - Volume Price and Revenue Forecast..... 190

Table 72 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 190

Table 73 All Clinical Testing - Volume Price and Revenue Forecast ..... 190

Table 74 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 191

Table 75 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 191

Table 76 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 191

Table 77 Clinical Chemistry - Volume Price and Revenue Forecast ..... 192

Table 78 Microbiology - Volume Price and Revenue Forecast..... 192

Table 79 Hematology - Volume Price and Revenue Forecast ..... 192

Table 80 Anatomic Pathology - Volume Price and Revenue Forecast..... 193

Table 81 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 193

Table 82 All Clinical Testing - Volume Price and Revenue Forecast ..... 193

Table 83 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 194

Table 84 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 194

Table 85 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 194

Table 86 Clinical Chemistry - Volume Price and Revenue Forecast ..... 195

Table 87 Microbiology - Volume Price and Revenue Forecast..... 195

Table 88 Hematology - Volume Price and Revenue Forecast ..... 195

Table 89 Anatomic Pathology - Volume Price and Revenue Forecast..... 196

Table 90 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 196

Table 91 All Clinical Testing - Volume Price and Revenue Forecast ..... 196

Table 92 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 197

Table 93 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 197

Table 94 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 197

Table 95 Clinical Chemistry - Volume Price and Revenue Forecast ..... 199

Table 96 Microbiology - Volume Price and Revenue Forecast..... 199

Table 97 Hematology - Volume Price and Revenue Forecast ..... 199

Table 98 Anatomic Pathology - Volume Price and Revenue Forecast..... 200

Table 99 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 200

Table 100 All Clinical Testing - Volume Price and Revenue Forecast ..... 200

Table 101 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 201

Table 102 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 201

Table 103 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 201

Table 104 Clinical Chemistry - Volume Price and Revenue Forecast ..... 202

Table 105 Microbiology - Volume Price and Revenue Forecast..... 202

Table 106 Hematology - Volume Price and Revenue Forecast ..... 202

Table 107 Anatomic Pathology - Volume Price and Revenue Forecast..... 203

Table 108 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 203

Table 109 All Clinical Testing - Volume Price and Revenue Forecast ..... 203

Table 110 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 204

Table 111 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 204

Table 112 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 204

Table 113 Clinical Chemistry - Volume Price and Revenue Forecast ..... 205

Table 114 Microbiology - Volume Price and Revenue Forecast..... 205

Table 115 Hematology - Volume Price and Revenue Forecast ..... 205

Table 116 Anatomic Pathology - Volume Price and Revenue Forecast..... 206

Table 117 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 206

Table 118 All Clinical Testing - Volume Price and Revenue Forecast ..... 206

Table 119 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 207

Table 120 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 207

Table 121 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 207

Table 122 Clinical Chemistry - Volume Price and Revenue Forecast ..... 208

Table 123 Microbiology - Volume Price and Revenue Forecast..... 208

Table 124 Hematology - Volume Price and Revenue Forecast ..... 208

Table 125 Anatomic Pathology - Volume Price and Revenue Forecast..... 209

Table 126 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 209

Table 127 All Clinical Testing - Volume Price and Revenue Forecast ..... 209

Table 128 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 210

Table 129 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 210

Table 130 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 210

Table 131 Clinical Chemistry - Volume Price and Revenue Forecast ..... 211

Table 132 Microbiology - Volume Price and Revenue Forecast..... 211

Table 133 Hematology - Volume Price and Revenue Forecast ..... 211

Table 134 Anatomic Pathology - Volume Price and Revenue Forecast..... 212

Table 135 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 212

Table 136 All Clinical Testing - Volume Price and Revenue Forecast ..... 212

Table 137 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 213

Table 138 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 213

Table 139 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 213

Table 140 Clinical Chemistry - Volume Price and Revenue Forecast ..... 214

Table 141 Microbiology - Volume Price and Revenue Forecast..... 214

Table 142 Hematology - Volume Price and Revenue Forecast ..... 214

Table 143 Anatomic Pathology - Volume Price and Revenue Forecast..... 215

Table 144 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 215

Table 145 All Clinical Testing - Volume Price and Revenue Forecast ..... 215

Table 146 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 216

Table 147 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 216

Table 148 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 216

Table 149 Clinical Chemistry - Volume Price and Revenue Forecast ..... 218

Table 150 Microbiology - Volume Price and Revenue Forecast..... 218

Table 151 Hematology - Volume Price and Revenue Forecast ..... 218

Table 152 Anatomic Pathology - Volume Price and Revenue Forecast..... 219

Table 153 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 219

Table 154 All Clinical Testing - Volume Price and Revenue Forecast ..... 219

Table 155 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 220

Table 156 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 220

Table 157 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 220

Table 158 Clinical Chemistry - Volume Price and Revenue Forecast ..... 221

Table 159 Microbiology - Volume Price and Revenue Forecast..... 221

Table 160 Hematology - Volume Price and Revenue Forecast ..... 221

Table 161 Anatomic Pathology - Volume Price and Revenue Forecast..... 222

Table 162 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 222

Table 163 All Clinical Testing - Volume Price and Revenue Forecast ..... 222

Table 164 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 223

Table 165 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 223

Table 166 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 223

Table 167 Clinical Chemistry - Volume Price and Revenue Forecast ..... 224

Table 168 Microbiology - Volume Price and Revenue Forecast..... 224

Table 169 Hematology - Volume Price and Revenue Forecast ..... 224

Table 170 Anatomic Pathology - Volume Price and Revenue Forecast..... 225

Table 171 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 225

Table 172 All Clinical Testing - Volume Price and Revenue Forecast ..... 225

Table 173 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 226

Table 174 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 226

Table 175 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 226

Table 176 Clinical Chemistry - Volume Price and Revenue Forecast ..... 227

Table 177 Microbiology - Volume Price and Revenue Forecast..... 227

Table 178 Hematology - Volume Price and Revenue Forecast ..... 227

Table 179 Anatomic Pathology - Volume Price and Revenue Forecast..... 228  
 Table 180 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 228  
 Table 181 All Clinical Testing - Volume Price and Revenue Forecast ..... 228  
 Table 182 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 229  
 Table 183 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 229  
 Table 184 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 229  
 Table 185 Clinical Chemistry - Volume Price and Revenue Forecast ..... 231  
 Table 186 Microbiology - Volume Price and Revenue Forecast..... 231  
 Table 187 Hematology - Volume Price and Revenue Forecast ..... 231  
 Table 188 Anatomic Pathology - Volume Price and Revenue Forecast..... 232  
 Table 189 Molecular Diagnostics - Volume Price and Revenue Forecast ..... 232  
 Table 190 All Clinical Testing - Volume Price and Revenue Forecast ..... 232  
 Table 191 Cardiac Biomarkers - Volume Price and Revenue Forecast..... 233  
 Table 192 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast ..... 233  
 Table 193 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast ..... 233  
 Table 194 2017 Clinical Lab Fee Schedule ..... 235

Table of Figures

Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 (\$Million) ..... 21